autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes

Autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes are a personalized cell therapy product created by isolating a patient’s own (autologous) peripheral blood mononuclear cells (PBMCs), genetically engineering them ex vivo with a retroviral vector to express the high-affinity DMF5-derived, HLA-A2-restricted, anti-MART‑1 (Melan-A) specific α/β T cell receptor, and expanding them for reinfusion. Upon administration, these engineered cytotoxic CD8+ and CD4+ lymphocytes specifically recognize and target melanoma cells expressing the MART‑1 antigen in the context of HLA-A*0201. The therapy is typically combined with preparative chemotherapy for host immune depletion, dendritic cell vaccination pulsed with MART‑126–35 peptide to boost in vivo expansion of transferred cells, and low-dose interleukin 2 to support persistence. This approach aims to induce tumor regression in patients with metastatic melanoma refractory to standard treatments[2][3][6].

Other names

autologous anti-MART-1 F5 TCR PBLMART-1 F5 TCR CTLMART1 F5 TCR CTLMART 1 F5 TCR CTLautologous anti-MART-1 F5 T-cell receptor cytolytic T lymphocyte